Effect of oral camostat mesilate on hematuria and/or proteinuria in children
Effect of oral camostat mesilate on hematuria and/or proteinuria in children
复制标题
DOI：
10.1007/s00467-003-1377-9
复制
发表时间：
2004-03-01
影响因子：
3
通讯作者：
Uchiyama, M
中科院分区：
文献类型：
--
作者：
Asami, T;Tomisawa, S;Uchiyama, M
观察口服甲磺酸加贝酯的衍生物卡莫司坦(CM)对原发性肾小球肾炎(GN)和Chance血尿和/或蛋白尿的影响。入选患者14例，男6例，女8例，年龄4~16岁，平均11岁零3个月。组织学和临床诊断：IgA肾病3例，非IgA肾病2例，无症状显着镜检血尿[高倍视野(X400)>100个红细胞]伴或不伴蛋白尿9例。经几个月的观察，确诊为持续性显着镜检血尿和/或蛋白尿时，给予中药口服(100 mg/d，2次/d)。14例患者中有10例(85.7%)在服药后1个月、1周至10个月(平均4个月)尿检结果恢复正常。血尿消失11例，蛋白尿消失4例。服药时间4~37个月，平均21.7+/-9.1个月。目前，在停止CM治疗3-12年后，9岁10个月至26岁6个月的儿童的尿检结果仍保持正常。总之，口服CM似乎与显著的镜检血尿和/或蛋白尿的减少有关。口服CM疗法可能是治疗儿童偶然性血尿和/或蛋白尿的一种实用的初级保健方法。
The effects of camostat mesilate (CM), a derivative of gabexate mesilate developed for oral use, on primary glomerulonephritis (GN) and chance hematuria and/or proteinuria were evaluated. Fourteen patients (6 males, 8 females) with a mean age of 11 years and 3 months (range 4-16 years) were enrolled. Histological and clinical diagnoses of the 14 patients were as follows: IgA nephropathy 3, non-IgA GN 2, and asymptomatic significant microscopic hematuria [more than 100 red blood cells per high-power field (x400)] with or without proteinuria 9. They were consecutively treated with oral CM (100 mg twice a day) when they were confirmed to have continuous significant microscopic hematuria and/or proteinuria after a few months of observational follow-up. Urinary findings were normalized in 10 of the 14 patients (85.7%) between 1 month 1 week and 10 months (mean 4 months) after administration of CM. Hematuria cleared in 11 of 13 patients, and proteinuria disappeared in 4 of 5 patients. The mean duration of CM administration was 21.7+/-9.1 months (range 4-37 months). At present, 3-12 years after discontinuation of CM therapy, their urinary findings remain normal at 9 years 10 months to 26 years 6 months of age. In conclusion, there appears to be an association between the oral use of CM and reduction in significant microscopic hematuria and/or proteinuria. Oral CM therapy could represent a practical primary care approach to chance hematuria and/or proteinuria in children.